AGP Executive Report
Last update: 6 hours agoNeurostimulation Breakthrough: A new post-approval real-world study reports sustained seizure reductions with NeuroPace’s responsive neurostimulation (RNS) system in drug-resistant focal epilepsy, with a median 82% drop in seizures at 3 years and many patients hitting 90%+ reductions. Oncology Dealmaking: Rigel Pharmaceuticals secured an exclusive global licensing agreement with Arvinas and Pfizer for Veppanu (vepdegestrant), expanding its Protac oncology push after FDA approval for ESR1-mutated ER+/HER2− advanced breast cancer. Obesity Maintenance: Eli Lilly says late-stage data show patients can maintain meaningful weight loss after switching from higher-dose injectable GLP-1s to lower-dose Zepbound or oral Foundayo. Regulatory/Access: The UK’s MHRA–NICE aligned approval pathway aims to speed NHS availability by syncing regulatory and health-tech assessment decisions. Care Delivery: NHS Blood and Transplant rolled out a “world first” VR-based eye retrieval training program to cut training time and boost cornea transplant capacity.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
